ArticleAdvances in experimental medicine and biology2022
Network Approaches for Precision Oncology.
Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Network-based approach elucidates critical genes in BRCA subtypes and chemotherapy response in triple negative breast cancer.iScience · 2024Article
- Inferring Diagnostic and Prognostic Gene Expression Signatures Across WHO Glioma Classifications: A Network-Based Approach.Bioinformatics and biology insights · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth of multi-omic tumour profile datasets along with knowledge of genome regulatory networks has created an unprecedented opportunity to advance precision oncology. Achieving this goal requires computational methods that can make sense of and combine heterogeneous data sources. Interpretability and integration of prior knowledge is of particular relevance for genomic models to minimize ungeneralizable models, promote rational treatment design, and make use of sparse genetic mutation data. While networks have long been used to capture genomic interactions at the levels of genes, proteins, and pathways, the use of networks in precision oncology is relatively new. In this chapter, I provide an introduction to network-based approaches used to integrate multi-modal data sources for patient stratification and patient classification. There is a particular emphasis on methods using patient similarity networks (PSNs) as part of the design. I separately discuss strategies for inferring driver mutations from individual patient mutation data. Finally, I discuss challenges and opportunities the field will need to overcome to achieve its full potential, with an outlook towards a clinic of the future.
Indexed as
Identifiers
35230690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.